Virax Biolabs Group is a biotechnology business based in the US. Virax Biolabs Group shares (VRAX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.88 – a decrease of 3.09% over the previous week. Virax Biolabs Group employs 17 staff and has a trailing 12-month revenue of around $156,419.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.88 |
|---|---|
| 52-week range | $0.60 - $7.63 |
| 50-day moving average | $2.19 |
| 200-day moving average | $1.53 |
| Wall St. target price | $20.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-3.36 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.92 from 2024-11-19
| 1 week (2024-11-13) | -1.03% |
|---|---|
| 1 month (2024-10-18) | 25.49% |
| 3 months (2024-08-20) | -46.07% |
| 6 months (2024-05-20) | 131.33% |
| 1 year (2023-11-20) | 668.00% |
|---|---|
| 2 years (2022-11-18) | -86.48% |
| 3 years (2021-11-17) | N/A |
| 5 years (2019-11-17) | N/A |
| Revenue TTM | $156,419 |
|---|---|
| Gross profit TTM | $-1,365 |
| Return on assets TTM | -49.9% |
| Return on equity TTM | -95.98% |
| Profit margin | 0% |
| Book value | $2.09 |
| Market Capitalization | $8.2 million |
TTM: trailing 12 months
We're not expecting Virax Biolabs Group to pay a dividend over the next 12 months.
Virax Biolabs Group's shares were split on a 1:10 basis on 17 December 2023 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Virax Biolabs Group shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Virax Biolabs Group shares which in turn could have impacted Virax Biolabs Group's share price.
Over the last 12 months, Virax Biolabs Group's shares have ranged in value from as little as $0.6 up to $7.63. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Virax Biolabs Group's is 1.925. This would suggest that Virax Biolabs Group's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Virax Biolabs Group Limited, a biotechnology company, distributes, markets, and sells diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, the United Kingdom.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.